Theravance Biopharma, Inc.
TBPH
$13.91
$0.251.83%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 431.75% | -16.42% | -82.46% | -41.88% | -5.65% |
| Total Depreciation and Amortization | -13.41% | -10.05% | -18.96% | 16.36% | -22.72% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -175.10% | -33.84% | -107.97% | -2.84% | 11.34% |
| Change in Net Operating Assets | 5,761.66% | 1,161.22% | 506.77% | 74.57% | 145.86% |
| Cash from Operations | 4,812.89% | 4,311.25% | -5.62% | -109.01% | 64.50% |
| Capital Expenditure | 5.56% | -- | 71.94% | 28.57% | 95.77% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1,109.48% | 78.94% | -- | -- | -128.27% |
| Cash from Investing | -1,096.24% | 79.89% | 2,416.99% | -82,752.38% | -127.44% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | -- | -5.78% | -- | -6.05% |
| Repurchase of Common Stock | -8.64% | 49.07% | 98.28% | 98.74% | 99.43% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -1,043.18% | 50.23% | 98.81% | 98.82% | 99.95% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2,387.22% | 409.57% | 144.86% | 32.27% | 90.87% |